AoE2Insights
  • Analyze game
  • Lobby Browser
  • Teams
  • Login
  • Head to Head

    5
    Wins
    1

    Matches across all leaderboards

  • Unranked
  • RM 1v1
  • RM Team
  • EW 1v1
  • -93 1,499
    Rating
    1,592 +93
    -298 1,827
    Highest Rating
    2,125 +298
    36.9 %
    Win Probability
    63.1 %
    83% Mongols
    Best Civ (WR)
    Koreans 100%
    17× Japanese
    Favorite Civ
    Ethiopians 29×
    83% Nomad
    Best Map (WR)
    Migration 86%

    MerlinAoE will win in roughly 12 out of 19 matches against LE | Emaxcito2.

    Rating Development

    -11 1,870 #946
    Rating
    #906 1,881 +11
    +48 1,988
    Highest Rating
    1,940 -48
    48.4 %
    Win Probability
    51.6 %
    -2,280 2,360
    Matches
    4,640 +2,280
    51.4%
    Win Rate
    50.6%
    -5
    Streak
    +3
    77% Magyars
    Best Civ (WR)
    Hindustanis 68%
    359× Dravidians
    Favorite Civ
    Georgians 411×
    80% Bogland
    Best Map (WR)
    Water Nomad 100%

    MerlinAoE will win in roughly 10 out of 19 matches against LE | Emaxcito2.

    Rating Development

    +20 1,562 #2157
    Rating
    #2859 1,542 -20
    -135 1,565
    Highest Rating
    1,700 +135
    52.9 %
    Win Probability
    47.1 %
    -3,212 337
    Matches
    3,549 +3,212
    55.8%
    Win Rate
    54.6%
    +1
    Streak
    -1
    100% Koreans
    Best Civ (WR)
    Tupi 86%
    29× Britons
    Favorite Civ
    Ethiopians 491×
    82% MegaRandom
    Best Map (WR)
    Enclosed 100%

    LE | Emaxcito2 will win in roughly 9 out of 17 matches against MerlinAoE.

    Rating Development

    -257 1,291
    Rating
    #90 1,548 +257
    -275 1,310
    Highest Rating
    1,585 +275
    18.6 %
    Win Probability
    81.4 %
    -150 16
    Matches
    166 +150
    75.0%
    Win Rate
    59.6%
    -1
    Streak
    +1
    80% Lithuanians
    Best Civ (WR)
    Tatars 86%
    Lithuanians
    Favorite Civ
    Poles 34×
    71% Aftermath
    Best Map (WR)
    Kawasan 83%

    MerlinAoE will win in roughly 13 out of 16 matches against LE | Emaxcito2.

    Rating Development